Clinical Trials
9 trialsNCT01346540 2025-02-12
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Boehringer Ingelheim
Phase 1 Completed
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT02225405 2024-05-08
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02668393 2021-01-29
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT02751385 2019-03-14
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT01684111 2016-01-18
VENUS-1
Aktion Bronchialkarzinom e.V.
Phase 1 Completed
NCT01683682 2015-01-26
VENUS-2
Aktion Bronchialkarzinom e.V.
Phase 1 Completed
NCT02182102 2014-07-18
Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02182232 2014-07-18
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed